Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06098001
Other study ID # BIO-2311
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 15, 2023
Est. completion date December 2023

Study information

Verified date October 2023
Source Brightseed
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim is to determine the bioavailability of the polyphenol fraction form a commercially available hemp hull fiber at two different amounts in generally healthy adults. Additional objectives include determining specific metabolites produced over a 24 to 48-hour period following the hemp fiber consumption. Subjects will consume a study pudding that will be used to deliver a low and a high dose fiber product. Blood samples will be collected to measure background levels of metabolites. At day 0 participants will consume a low dose study product and day 6 the high dose study product and provide blood samples over an 8 hr period after study product consumption, to be followed by a 24 hr blood sample and 48 hr blood sample. Additionally following the low / high dose study product 24 and 48 h urine samples will be collected.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date December 2023
Est. primary completion date November 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - BMI 18.50 - 29.99 - non Tobacco or vaping user - non-user of hemp products within 12 months of first visit - Willing to stop dietary supplement use within 7 days of visit - Generally heathy Exclusion Criteria: - History or presence of clinically important disorders that may affect subjects ability to participate in the study - Clinically important GI conditions that potentially interfere with evaluation of study product - Uncontrolled hypertension or unstable use of antihypertensives - Recent antibiotic use - extreme dietary habits - recent or currently on weight loss regimen - Known allergy or sensitivity to the study products - History or presence of cancer in prior 2 years, except for non-melanoma skin cancer - History of any major trauma or major surgical event within 2 months of first visit - Pregnancy or willing to become pregnant during study - Alcohol abuses - Exposure to any non-registered drug product within 30 days prior to first visit

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Low dose dietary fiber
Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design
High dose dietary fiber
Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design

Locations

Country Name City State
United States Biofortis Addison Illinois

Sponsors (3)

Lead Sponsor Collaborator
Brightseed Biofortis Mérieux NutriSciences, University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood concentration of phenolics from 0 to 8 hours 0 to 8 hours after consumption
Secondary Blood concentration of phenolics 0 to 24 hours 0 to 24 hours after consumption
Secondary Urine concentration of phenolics 24 and 48 hours after consumption cumulative total phenolics at 24 and 48 hours
Secondary Concentration of Phenolic metabolites in blood and urine Blood concnetrations at 0 to 8 hours post consumption and cumulative urine concentration 24 hours and 48 hours post consumption
See also
  Status Clinical Trial Phase
Completed NCT06043739 - Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects Phase 1
Completed NCT02557139 - Bioavailability of Belumosudil (KD025) in Healthy Male Subjects Phase 1
Completed NCT02010944 - A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels Phase 1
Not yet recruiting NCT01136551 - Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A N/A
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT04097808 - Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects N/A
Completed NCT01912144 - Absorption of Phenolic Acids From Coffee in Humans N/A
Completed NCT03915626 - Effect of Heat on Rivastigmine TDS Products Early Phase 1
Completed NCT01448772 - Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions Phase 1
Completed NCT01464450 - Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants Phase 1
Completed NCT01181973 - Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects Phase 1
Completed NCT00858767 - Arabic Gum-Absorption Study N/A
Completed NCT04113564 - Absolute Oral Bioavailability of Remimazolam Phase 1
Completed NCT04645394 - Bioavailability of Anthocyanins From Aronia Extract in Healthy Men - a Pilot Study N/A
Completed NCT03485885 - Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects
Completed NCT05840848 - Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males N/A
Completed NCT02986529 - A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects Phase 1
Completed NCT01789359 - Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding N/A
Completed NCT01638143 - Bio-equivalence Study N/A
Completed NCT00755872 - Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate Phase 1